| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal NG28: Type 2 diabetes in adults: management |
|
Medicine details |
|
| Medicine name | exenatide (Bydureon®) |
| Formulation | 2 mg powder and solvent for prolonged-release suspension for injection |
| Reference number | 1071 |
| Indication | Treatment of type 2 diabetes mellitus in combination with metformin, sulphonylurea, thiazolidinedione, metformin and sulphonylurea or metformin and thiazolidinedione in adults who have not achieved adequate glycaemic control on maximally tolerated doses of these oral therapies |
| Company | Eli Lilly & Co Ltd |
| BNF chapter | Endocrine system |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 24/08/2011 |
| NICE guidance | |